Pentadeca Arginate vs GHK-Cu

Side-by-side comparison of Pentadeca Arginate, GHK-Cu — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute Pentadeca Arginate Pentadeca Arginate (PDA) — BPC-157 Arginine Variant Recovery GHK-Cu Glycyl-L-Histidyl-L-Lysine Copper Complex Recovery
Basics
Molecular type Pentadecapeptide Arginine AnalogueCopper-Binding Tripeptide
Amino acids 153
Molecular weight 1,476.6 Da340.4 Da
Half-life ~4–6 hrs (estimated)Short (minutes to hours)
Route(s) Subcutaneous, Intramuscular, Oral (research)Subcutaneous, Topical (skin), IV (research)
Mechanism & Research
Primary mechanism PDA shares BPC-157's primary mechanism of action: nitric oxide (NO) synthase upregulation, VEGFR2-mediated angiogenesis, and connective tissue repair signalling. The arginine modification may further amplify NO pathway a… GHK-Cu forms a stable complex with copper(II), which is essential for its biological activity. The copper complex activates collagenase and other metalloproteinases that remodel damaged extracellular matrix while simulta…
Research status Research Compound Research Compound
Evidence summary PDA is a newer research compound with a smaller published evidence base than BPC-157. Most researchers extrapolate from BPC-157's extensive preclinical data given the structural and mechanistic similarity. Direct compara… GHK-Cu is one of the most thoroughly researched cosmetic and wound-healing peptides. Topical GHK-Cu is commercially used in skincare. Deeper systemic applications (anti-aging, neuroprotection, systemic collagen support) …
Protocol & Dosing
Typical dose 200–500 mcg per injection1–2 mg/day (SC); topical as needed
Frequency Once or twice dailyDaily
Duration 4–12 weeks8–12 weeks
Timing Near injury site when possible; any timeAny time of day
Safety
Common side effects
  • Injection site redness or bruising
  • Mild nausea (oral form)
  • Transient dizziness
  • Warmth at injection site
  • Topical: mild skin irritation at application site
  • Injectable: injection site redness
  • Copper taste (topical — rare)
Contraindications
  • Active malignancy (angiogenesis concern)
  • Pregnancy (no safety data)
  • Concurrent anticoagulant therapy (caution)
  • Wilson's disease (copper metabolism disorder)
  • Known copper sensitivity
  • Pregnancy (insufficient systemic safety data)
Anti-doping Prohibited (WADA S0) Not Prohibited
Deeper reading
Related peptides BPC-157, TB-500, GHK-Cu BPC-157, Epithalon, LL-37
Full profile Read full Pentadeca Arginate profile → Read full GHK-Cu profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.